Clinical Trials Sponsored by NSABP Foundation Inc

Total 1002 results

NSABP Foundation Inc

Completed

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Rectal Cancer

United States
NSABP Foundation Inc

Withdrawn

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

Colorectal Cancer

United States
NSABP Foundation Inc

Completed

A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIB Breast Cancer | Locally Advanced

United States
NSABP Foundation Inc

Completed

NSABP Patient Registry and Biospecimen Profiling Repository

Colorectal Cancer

United States
NSABP Foundation Inc

Completed

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Colorectal Cancer Metastatic

United States
GlaxoSmithKline
NSABP Foundation Inc

Completed

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Neoplasms, Breast

United States, Canada
NSABP Foundation Inc
Bayer

Terminated

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO)

Stage III (IIIB or IIIC) Colon Cancer

United States
NSABP Foundation Inc
Sanofi

Withdrawn

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer
NSABP Foundation Inc
Amgen

Withdrawn

Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum

Neoplasm Metastasis | Rectal Cancer
NSABP Foundation Inc
AstraZeneca

Completed

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Breast Neoplasms

United States
NSABP Foundation Inc
GlaxoSmithKline

Unknown

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Invasive Breast Cancer

United States, Canada, Puerto Rico
NSABP Foundation Inc
Pfizer

Completed

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
Eisai Inc.

Completed

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Breast Cancer | HER2-negative Breast Cancer

United States, Canada
NSABP Foundation Inc
Celgene Corporation

Completed

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Breast Neoplasms

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Active, not recruiting

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Metastatic Colorectal Cancer

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Breast Cancer

United States, Canada, Puerto Rico, Italy, Spain
ETOP IBCSG Partners Foundation
NSABP Foundation Inc

Completed

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer (CALOR)

Breast Cancer

Spain, United States, Australia, Belgium, Switzerland, Canada, Peru, Netherlands, Hungary, South Africa
NSABP Foundation Inc
Novartis Pharmaceuticals; Natera, Inc.

Withdrawn

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Colon Cancer

United States
Sanofi
Regeneron Pharmaceuticals; NSABP Foundation Inc

Completed

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)

Neoplasm Metastasis | Colorectal Neoplasms

Italy, Austria, Estonia, Spain, South Africa, Belgium, Puerto Rico, United Kingdom, Sweden, United States, Argentina, Australia, Brazil, Chile, Czech Republic, Denmark, France, Germany, Greece, Korea, Republic of, Netherlands, New... and more
NSABP Foundation Inc
Genentech, Inc.; Celcuity, LLC

Recruiting

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

HER2-negative Breast Cancer

United States
Exact Sciences Corporation
NSABP Foundation Inc

Recruiting

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer (MRD)

Colorectal Cancer

United States
NSABP Foundation Inc
Bristol-Myers Squibb

Completed

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Metastatic Colorectal Cancer

United States
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.

Active, not recruiting

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Triple Negative Breast Cancer

United States, Canada
NSABP Foundation Inc
Genentech, Inc.; US Oncology Research

Completed

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Breast Cancer

United States, Ireland
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Terminated

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Colorectal Cancer | Precancerous Condition

United States, Canada
NSABP Foundation Inc
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Breast Cancer

United States, Puerto Rico
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer

Breast Cancer

United States, Canada
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Unknown

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Breast Cancer

United States, Canada, Puerto Rico
NSABP Foundation Inc
National Cancer Institute (NCI)

Unknown

Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2

Breast Cancer
National Cancer Institute (NCI)
NSABP Foundation Inc

Completed

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Liver Metastases | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery

Colorectal Cancer
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Breast Cancer

United States, Canada
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Breast Cancer

United States, Canada, Puerto Rico
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Breast Cancer

United States, Canada
National Cancer Institute (NCI)
NSABP Foundation Inc

Completed

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Colon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Breast Cancer

Canada, United States, Puerto Rico
NSABP Foundation Inc
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

Colorectal Cancer | Metastatic Cancer

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Withdrawn

Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45

Breast Cancer | Fatigue
NSABP Foundation Inc
National Cancer Institute (NCI)

Terminated

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

Colorectal Cancer

United States
NSABP Foundation Inc
Pfizer; Genomic Health®, Inc.

Completed

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Breast Cancer

United States, Canada
Eli Lilly and Company
NSABP Foundation Inc

Active, not recruiting

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

Breast Cancer

United States, Spain, China, Germany, Taiwan, United Kingdom, Canada, Singapore, Italy, Australia, Japan, Hungary, Russian Federation, Belgium, New Zealand, Austria, India, Saudi Arabia, France, Czechia, Korea, Republic of, Finland, Argentin... and more
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Breast Cancer

United States, Canada
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Breast Cancer

United States
Eli Lilly and Company
NSABP Foundation Inc

Terminated

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab (FC-4)

Rectal Cancer | Colon Cancer

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Unknown

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Depression | Breast Cancer | Fatigue | Sleep Disorders

United States, Canada
NSABP Foundation Inc
National Cancer Institute (NCI)

Unknown

Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial

Breast Cancer
NSABP Foundation Inc
National Cancer Institute (NCI)

Unknown

Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28

Breast Cancer

3

Subscribe